Retraction of: Microrna-34a-Upregulated Retinoic Acid-Inducible Gene-I Promotes Apoptosis and Delays Cell Cycle Transition in Cervical Cancer Cells, by Wang J-H, et al. (DNA Cell Biol (2016) 35:6 (267-279) DOI: 10.1089/dna.2015.3130);MicroRNA-34a-Upregulated Retinoic Acid-Inducible Gene-I Promotes Apoptosis and Delays Cell Cycle Transition in Cervical Cancer Cells

DNA and Cell Biology

Volumn 35, Issue 6, 2016, Pages 267-279

  Wang, Jing Hua ^a   Zhang, Le ^a   Ma, Yu Wei ^a   Xiao, Jing ^a   Zhang, Yi ^a   Liu, Min ^a   Tang, Hua ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 34A; RETINOIC ACID INDUCIBLE PROTEIN I; DDX58 PROTEIN, HUMAN; MICRORNA; MIRN34 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MIGRATION INHIBITION; PHENOTYPE; PRIORITY JOURNAL; RESCUE PERSONNEL; S PHASE CELL CYCLE CHECKPOINT; TUMOR INVASION; UPREGULATION; UTERINE CERVIX CANCER; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR SUPPRESSOR GENE; UTERINE CERVIX TUMOR;

3' UNTRANSLATED REGIONS; DEAD BOX PROTEIN 58; FEMALE; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HELA CELLS; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; UTERINE CERVICAL NEOPLASMS;

EID: 84973461693     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2015.3130.retract     Document Type: Erratum

References (54)

1. Alexopoulou, L., Holt, A.C., Medzhitov, R., and Flavell, R.A. (2001). Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 413, 732-738.
2. Bartel, D.P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233.
3. Besch, R., Poeck, H., Hohenauer, T., Senft, D., Hacker, G., Berking, C., et al. (2009). Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. The Journal of clinical investigation 119, 2399-2411.
4. Craig, V.J., Cogliatti, S.B., Imig, J., Renner, C., Neuenschwander, S., Rehrauer, H., et al. (2011). Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 117, 6227-6236.
5. Cui, S., Eisenacher, K., Kirchhofer, A., Brzozka, K., Lammens, A., Lammens, K., et al. (2008). The C-terminal regulatory domain is the RNA 5¢-triphosphate sensor of RIG-I. Mol Cell 29, 169-179.
6. Gee, P., Chua, P.K., Gevorkyan, J., Klumpp, K., Najera, I., Swinney, D.C., et al. (2008). Essential role of the N-terminal domain in the regulation of RIG-I ATPase activity. J Biol Chem 283, 9488-9496.
7. Giza, D.E., Vasilescu, C., and Calin, G.A. (2014). MicroRNAs and ceRNAs: therapeutic implications of RNA networks. Expert Opin Biol Ther 14, 1285-1293.
8. Hou, J., Wang, P., Lin, L., Liu, X., Ma, F., An, H., et al. (2009). MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol 183, 2150-2158.
9. Hu, J., He, Y., Yan, M., Zhu, C., Ye, W., Zhu, H., et al. (2013). Dose dependent activation of retinoic acid-inducible gene-I promotes both proliferation and apoptosis signals in human head and neck squamous cell carcinoma. PloS One 8, e58273.
10. Hu, J., Nistal-Villan, E., Voho, A., Ganee, A., Kumar, M., Ding, Y., et al. (2010). A common polymorphism in the caspase recruitment domain of RIG-I modifies the innate immune response of human dendritic cells. J Immunol 185, 424-432.
11. Kang, H.W., Wang, F., Wei, Q., Zhao, Y.F., Liu, M., Li, X., et al. (2012). miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. FEBS Lett 586, 897-904.
12. Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., et al. (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105.
13. Kim, B.M., and Choi, M.Y. (2012). Non-canonical microRNAs miR-320 and miR-702 promote proliferation in Dgcr8- deficient embryonic stem cells. Biochem Biophys Res Commun 426, 183-189.
14. Kim, S., Lee, S., Shin, J., Kim, Y., Evnouchidou, I., Kim, D., et al. (2011). Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1. Nat Immunol 12, 984-991.
15. Kinlen, L. (2004). Infections and immune factors in cancer: the role of epidemiology. Oncogene 23, 6341-6348.
16. Kolakofsky, D., Kowalinski, E., and Cusack, S. (2012). A structure-based model of RIG-I activation. RNA 18, 2118-2127.
17. Kowalinski, E., Lunardi, T., McCarthy, A.A., Louber, J., Brunel, J., Grigorov, B., et al. (2011). Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell 147, 423-435.
18. Kumar, B., Yadav, A., Lang, J., Teknos, T.N., and Kumar, P. (2012). Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PloS One 7, e37601.
19. Kutikhin, A.G., and Yuzhalin, A.E. (2012). Inherited variation in pattern recognition receptors and cancer: dangerous liaisons? Cancer Manage Res 4, 31-38.
20. Lai, M., Du, G., Shi, R., Yao, J., Yang, G., Wei, Y., et al. (2015). MiR-34a inhibits migration and invasion by regulating the SIRT1/p53 pathway in human SW480 cells. Mol Med Rep 11, 3301-3307.
21. Li, X.J., Ren, Z.J., and Tang, J.H. (2014a). MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis 5, e1327.
22. Li, X.Y., Jiang, L.J., Chen, L., Ding, M.L., Guo, H.Z., Zhang, W., et al. (2014b). RIG-I modulates Src-mediated AKT activation to restrain leukemic stemness. Mol Cell 53, 407-419.
23. Liang, J., Li, Y., Daniels, G., Sfanos, K., De Marzo, A., Wei, J., et al. (2015). LEF1 targeting EMT in prostate cancer invasion is regulated by miR-34a. Mol Cancer Res 13, 681-688.
24. Liu, T., Tang, H., Lang, Y., Liu, M., and Li, X. (2009). MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 273, 233-242.
25. Liu, Z., Dou, C., Jia, Y., Li, Q., Zheng, X., Yao, Y., et al. (2015). RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9. Int J Oncol 46, 1710-1720.
26. Ma, C., Qi, Y., Shao, L., Liu, M., Li, X., and Tang, H. (2013a). Downregulation of miR-7 upregulates Cullin 5 (CUL5) to facilitate G1/S transition in human hepatocellular carcinoma cells. IUBMB Life 65, 1026-1034.
27. Ma, Y., Qin, H., and Cui, Y. (2013b). MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway. Biochem Biophys Res Commun 441, 958-963.
28. Nachmani, D., Lankry, D., Wolf, D.G., and Mandelboim, O. (2010). The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat Immunol 11, 806-813.
29. Narisawa-Saito, M., and Kiyono, T. (2007). Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci 98, 1505-1511.
30. O'Neill, L.A., and Bowie, A.G. (2011). The powerstroke and camshaft of the RIG-I antiviral RNA detection machine. Cell 147, 259-261.
31. Ovsyannikova, I.G., Haralambieva, I.H., Dhiman, N., O'Byrne, M.M., Pankratz, V.S., Jacobson, R.M., et al. (2010). Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. J Infect Dis 201, 207-213.
32. Pang, R.T., Leung, C.O., Ye, T.M., Liu, W., Chiu, P.C., Lam, K.K., et al. (2010). MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 31, 1037-1044.
33. Pichlmair, A., Schulz, O., Tan, C.P., Naslund, T.I., Liljestrom, P., Weber, F., et al. (2006). RIG-I-mediated antiviral responses to single-stranded RNA bearing 5¢-phosphates. Science 314, 997-1001.
34. Pothlichet, J., Burtey, A., Kubarenko, A.V., Caignard, G., Solhonne, B., Tangy, F., et al. (2009). Study of human RIG-I polymorphisms identifies two variants with an opposite impact on the antiviral immune response. PloS One 4, e7582.
35. Pothlichet, J., Niewold, T.B., Vitour, D., Solhonne, B., Crow, M.K., and Si-Tahar, M. (2011). A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol Med 3, 142-152.
36. Reshmi, G., and Pillai, M.R. (2008). Beyond HPV: oncomirs as new players in cervical cancer. FEBS Lett 582, 4113-4116.
37. Schaar, D.G., Medina, D.J., Moore, D.F., Strair, R.K., and Ting, Y. (2009). miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation. Exp Hematol 37, 245-255.
38. Schlee, M. (2013). Master sensors of pathogenic RNA - RIG-I like receptors. Immunobiology 218, 1322-1335.
39. Siemens, H., Jackstadt, R., Hunten, S., Kaller, M., Menssen, A., Gotz, U., et al. (2011). miR-34 and SNAIL form a doublenegative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 10, 4256-4271.
40. Song, B., Ji, W., Guo, S., Liu, A., Jing, W., Shao, C., et al. (2014). miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I. FEBS Lett 588, 4375-4381.
41. Vasseur, E., Patin, E., Laval, G., Pajon, S., Fornarino, S., Crouau-Roy, B., et al. (2011). The selective footprints of viral pressures at the human RIG-I-like receptor family. Hum Mol Genet 20, 4462-4474.
42. Wan, H.Y., Li, Q.Q., Zhang, Y., Tian, W., Li, Y.N., Liu, M., et al. (2014). MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells. Cancer Lett 355, 148-158.
43. Wang, R., Tian, S., Wang, H.B., Chu, D.P., Cao, J.L., Xia, H.F., et al. (2014). MiR-185 is involved in human breast carcinogenesis by targeting Vegfa. FEBS Lett 588, 4438-4447.
44. Wang, T., Li, F., and Tang, S. (2015). MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2. Oncol Lett 9, 967-971.
45. Wen, Z., Lei, Z., Jin-An, M., Xue-Zhen, L., Xing-Nan, Z., and Xiu-Wen, D. (2014). The inhibitory role of miR-214 in cervical cancer cells through directly targeting mitochondrial transcription factor A (TFAM). Eur J Gynaecol Oncol 35, 676-682.
46. Wilting, S.M., van Boerdonk, R.A., Henken, F.E., Meijer, C.J., Diosdado, B., Meijer, G.A., et al. (2010). Methylationmediated silencing and tumour suppressive function of hsamiR- 124 in cervical cancer. Mol Cancer 9, 167.
47. Xiao, X., Chen, B., Liu, X., Liu, P., Zheng, G., Ye, F., et al. (2014a). Diallyl disulfide suppresses SRC/Ras/ERK signalingmediated proliferation and metastasis in human breast cancer by up-regulating miR-34a. PloS One 9, e112720.
48. Xiao, Z., Li, C.H., Chan, S.L., Xu, F., Feng, L., Wang, Y., et al. (2014b). A small-molecule modulator of the tumorsuppressor miR34a inhibits the growth of hepatocellular carcinoma. Cancer Res 74, 6236-6247.
49. Yee, C., Krishnan-Hewlett, I., Baker, C.C., Schlegel, R., and Howley, P.M. (1985). Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol 119, 361-366.
50. Yin, M., Wang, X., Yao, G., Lu, M., Liang, M., Sun, Y., et al. (2014). Transactivation of micrornA-320 by microRNA-383 regulates granulosa cell functions by targeting E2F1 and SF-1 proteins. J Biol Chem 289, 18239-18257.
51. Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., et al. (2004). The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5, 730-737.
52. Yoneyama, M., Onomoto, K., Jogi, M., Akaboshi, T., and Fujita, T. (2015). Viral RNA detection by RIG-I-like receptors. Curr Opin Immunol 32, 48-53.
53. Zhang, Y., Dai, J., Deng, H., Wan, H., Liu, M., Wang, J., et al. (2015). miR-1228 promotes the proliferation and metastasis of hepatoma cells through a p53 forward feedback loop. Br J Cancer 112, 365-374.
54. Zhou, C., Shen, L., Mao, L., Wang, B., Li, Y., and Yu, H. (2015). miR-92a is upregulated in cervical cancer and promotes cell proliferation and invasion by targeting FBXW7. Biochem Biophys Res Commun 458, 63-69.